减少血液系统恶性肿瘤患者感染的干预措施:系统综述与荟萃分析
该系统综述与荟萃分析纳入21项已完成的随机对照试验,评估预防性免疫球蛋白、抗生素和疫苗在慢性淋巴细胞白血病、非霍奇金淋巴瘤和多发性骨髓瘤患者中的疗效与安全性。预防性免疫球蛋白使临床记录感染风险降低28%(RR 0.72,95%CI 0.54-0.96),疫苗使风险降低63%(RR 0.37,95%CI 0.30-0.45),预防性抗生素未降低风险,无干预降低全因死亡率。
要点
- 预防性免疫球蛋白使临床记录感染风险降低28%(RR 0.72,95%CI 0.54-0.96)。
- 疫苗使临床记录感染风险降低63%(RR 0.37,95%CI 0.30-0.45)。
- 预防性抗生素未降低感染风险,且免疫球蛋白和抗生素增加不良事件风险。
核心结论
- 预防性免疫球蛋白和疫苗可降低临床记录感染风险,预防性抗生素未降低风险,无干预降低全因死亡率。
- 鉴于许多研究存在高偏倚风险, findings应谨慎解读,亟需高质量当代试验确立不同感染预防方法的有效性。
研究设计与样本
- 系统综述与荟萃分析,纳入评估预防性免疫球蛋白、抗生素和疫苗在成人慢性淋巴细胞白血病、非霍奇金淋巴瘤和多发性骨髓瘤患者中疗效与安全性的随机对照试验。
- 检索PubMed(MEDLINE)、EMBASE和Cochrane注册库至2021年1月9日,共筛选10576项研究,纳入21项已完成随机对照试验和1项正在进行的研究。
- 8项评估预防性免疫球蛋白(n=370;其中7项发表于2000年前),5项评估预防性抗生素(n=1587),7项评估疫苗(n=3996),1项比较免疫球蛋白与抗生素(n=60)。
- 二分类数据以相对风险(RR)及95%置信区间(CI)表示,采用随机效应模型合并。
- 本综述注册号为PROSPERO CRD42017070825。
主要发现
- 预防性免疫球蛋白使临床记录感染风险降低28%(n=2项试验;RR 0.72,95%CI 0.54-0.96)。
- 疫苗使临床记录感染风险降低63%(RR 0.37,95%CI 0.30-0.45)。
- 预防性抗生素未降低临床记录感染风险。
- 无干预降低全因死亡率。
- 预防性免疫球蛋白和抗生素增加不良事件风险。
局限性
- 许多研究存在高偏倚风险, findings应谨慎解读。
- 亟需高质量当代试验确立不同感染预防方法的有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired hypogammaglobulinemia is common in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). No previous systematic reviews (SRs) have compared different approaches to infection prevention. We sought to assess the efficacy and safety of prophylactic immunoglobulin, antibiotics, and vaccination in these patients. We performed an SR and meta-analysis of randomized controlled trials (RCTs) evaluating the efficacy and safety of prophylactic immunoglobulin, antibiotics, and vaccination in adult patients with hematological malignancies commonly associated with acquired hypogammaglobulinemia, specifically, CLL, NHL, and MM. We searched PubMed (MEDLINE), EMBASE, and Cochrane Registry up to 9 January 2021. Results for dichotomous data were expressed as relative risk (RR) with 95% confidence interval (CI) and pooled in a random-effects model. This review was registered with PROSPERO CRD42017070825. From 10 576 studies screened, there were 21 completed RCTs and 1 ongoing. Of these, 8 evaluated prophylactic immunoglobulin (n = 370; 7 published before 2000), 5 evaluated prophylactic antibiotics (n = 1587), 7 evaluated vaccination (n = 3996), and 1 compared immunoglobulin to antibiotics (n = 60). Prophylactic immunoglobulin reduced the risk of clinically documented infection (CDI) by 28% (n = 2 trials; RR, 0.72; 95% CI, 0.54-0.96), and vaccination reduced the risk by 63% (RR, 0.37; 95% CI, 0.30-0.45). Prophylactic antibiotics did not reduce the risk. No intervention reduced all-cause mortality. Prophylactic immunoglobulin and antibiotics increased the risk of adverse events. Findings should be interpreted with caution, given the high risk of bias in many studies. There is a clear need for high-quality contemporary trials to establish the effectiveness of different approaches to preventing infection.
引用
- Chai KL, Wong J, Weinkove R, et al. Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. Blood Adv. 2023. PMID: 35882473. doi:10.1182/bloodadvances.2022008073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。